Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bausch & Lomb CorpBLCO · Entity 3756 | Director | May 26, 2026 | May 28, 2026 |
| Bausch Health Companies Inc.BHC · Entity 4363 | Director | May 19, 2023 | May 19, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bausch & Lomb Corp
Report date May 26, 2026 · Filed May 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Shares, No Par ValueSEC Table I · non-derivative | Direct | 85,233 |
Reported balance
After 2026-05-26 transaction · row 1
1 source rowRow 1 · 2026-05-26 · Grant · Acquired 15,842 · Balance 85,233 F1: Reflects the annual grant of restricted share units ("RSUs") to non-employee directors under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, as amended and restated. Vested RSUs are settled in common shares, no par value, of Bausch + Lomb Corporation. The RSUs are scheduled to vest on the date immediately preceding the conclusion of the next annual meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the annual grant of restricted share units ("RSUs") to non-employee directors under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, as amended and restated. Vested RSUs are settled in common shares, no par value, of Bausch + Lomb Corporation. The RSUs are scheduled to vest on the date immediately preceding the conclusion of the next annual meeting of shareholders.
Bausch Health Companies Inc.
Report date May 19, 2023 · Filed May 19, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Shares, No Par ValueSEC Table I · non-derivative | Direct | 161,516 |
Reported balance
After 2023-05-19 transaction · row 1
1 source rowRow 1 · 2023-05-19 · Grant · Acquired 29,205 · Balance 161,516 F1: Represents the award of restricted share units ("RSUs") granted to non-employee directors of the Issuer on the third business day following their election at the Issuer's Annual Meeting of Shareholders. The RSUs have a grant date value equal to $250,000, vest immediately prior to the Issuer's next Annual Meeting of Shareholders, and are settled in common shares, no par value, of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the award of restricted share units ("RSUs") granted to non-employee directors of the Issuer on the third business day following their election at the Issuer's Annual Meeting of Shareholders. The RSUs have a grant date value equal to $250,000, vest immediately prior to the Issuer's next Annual Meeting of Shareholders, and are settled in common shares, no par value, of the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 26, 2026 Filed May 28, 2026 21:09 UTC | Bausch & Lomb Corp BLCO · Entity 3756 | GrantCommon Shares, No Par Value | 15,842 | $15.78 | $249,986.76 |
DisclosureSEC source: 0001860742-26-000081 · form4.xml · nonDerivative · entry 1 Ross Thomas W. Sr. · CIK 0001669396 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,233 F1 · shares: Reflects the annual grant of restricted share units ("RSUs") to non-employee directors under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, as amended and restated. Vested RSUs are settled in common shares, no par value, of Bausch + Lomb Corporation. The RSUs are scheduled to vest on the date immediately preceding the conclusion of the next annual meeting of shareholders. Read SEC document |
| March 03, 2026 Filed Mar 4, 2026 21:18 UTC | Bausch & Lomb Corp BLCO · Entity 3756 | GrantCommon Shares, No Par Value | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001860742-26-000053 · form4.xml · nonDerivative · entry 2 Ross Thomas W. Sr. · CIK 0001669396 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,391 F2 · shares: Represents matching restricted share units ("MRSUs") granted to the reporting person in connection with the open market purchase of common shares reported on Table I above, pursuant to the issuer's matching share program. One-third of the MRSUs will vest on each of the first, second, and third anniversaries following the date of grant, subject to the reporting person's continued service (except in limited circumstances). Read SEC document |
| March 03, 2026 Filed Mar 4, 2026 21:18 UTC | Bausch & Lomb Corp BLCO · Entity 3756 | PurchaseCommon Shares, No Par Value | 4,500 | $17.68 | $79,555.50 |
DisclosureSEC source: 0001860742-26-000053 · form4.xml · nonDerivative · entry 1 Ross Thomas W. Sr. · CIK 0001669396 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,891 F1 · price: Reflects a weighted average price. These shares were purchased in multiple transactions at prices ranging from $17.672 to $17.690 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| May 27, 2025 Filed May 28, 2025 20:10 UTC | Bausch & Lomb Corp BLCO · Entity 3756 | GrantCommon Shares, No Par Value | 20,338 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-015806 · form4.xml · nonDerivative · entry 1 Ross Thomas W. Sr. · CIK 0001669396 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,391 F1 · shares: Reflects the annual grant of restricted share units ("RSUs") to non-employee directors under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, as amended and restated. Vested RSUs are settled in common shares, no par value, of Bausch + Lomb Corporation. The RSUs are scheduled to vest immediately prior to the next annual meeting of shareholders. Read SEC document |
| August 02, 2024 Filed Aug 6, 2024 22:06 UTC | Bausch & Lomb Corp BLCO · Entity 3756 | GrantCommon Shares, No Par Value | 14,696 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-021760 · form4.xml · nonDerivative · entry 1 Ross Thomas W. Sr. · CIK 0001669396 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,053 F1 · shares: Reflects the annual grant of restricted stock units ("RSUs") to non-employee directors under the Amended and Restated Bausch + Lomb Corporation 2022 Omnibus Incentive Plan. Vested RSUs are settled in common shares, no par value, of Bausch + Lomb Corporation. The RSUs are scheduled to vest immediately prior to the next annual meeting of shareholders. Read SEC document |
| May 19, 2023 Filed May 19, 2023 20:24 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantCommon Shares, No Par Value | 29,205 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-016300 · form4.xml · nonDerivative · entry 1 Ross Thomas W. Sr. · CIK 0001669396 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,516 F1 · shares: Represents the award of restricted share units ("RSUs") granted to non-employee directors of the Issuer on the third business day following their election at the Issuer's Annual Meeting of Shareholders. The RSUs have a grant date value equal to $250,000, vest immediately prior to the Issuer's next Annual Meeting of Shareholders, and are settled in common shares, no par value, of the Issuer. Read SEC document |
| May 04, 2023 Filed May 5, 2023 20:32 UTC | Bausch & Lomb Corp BLCO · Entity 3756 | GrantCommon Shares, No Par Value | 12,857 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-014713 · form4.xml · nonDerivative · entry 1 Ross Thomas W. Sr. · CIK 0001669396 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,357 F1 · shares: Reflects the annual grant of restricted stock units ("RSUs") to non-employee directors under the Amended and Restated Bausch + Lomb Corporation 2022 Omnibus Incentive Plan. Vested RSUs are settled in common shares, no par value, of Bausch + Lomb Corporation. The RSUs are scheduled to vest immediately prior to the next annual meeting of shareholders. Read SEC document |
| June 24, 2022 Filed Jun 28, 2022 20:45 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantCommon Shares, No Par Value | 34,387 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-018206 · form4.xml · nonDerivative · entry 1 Ross Thomas W. Sr. · CIK 0001669396 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,311 F1 · shares: Represents the award of restricted share units ("RSUs") granted to non-employee directors of the Issuer on the third business day following their election at the Issuer's Annual Meeting of Shareholders. The RSUs have a grant date value equal to $250,000, vest immediately prior to the Issuer's next Annual Meeting of Shareholders, and are settled in common shares, no par value, of the Issuer. Read SEC document |
| May 10, 2022 Filed May 12, 2022 23:37 UTC | Bausch & Lomb Corp BLCO · Entity 3756 | GrantCommon Shares, No Par Value | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-017855 · doc4.xml · nonDerivative · entry 1 Ross Thomas W. Sr. · CIK 0001669396 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 F1 · shares: Reflects the grant of restricted stock units ("RSUs") under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (the "Plan"). Vested RSUs are settled in common shares, no par value, of Bausch + Lomb Corporation (the "Company"). F2 · shares: The RSUs are scheduled to vest on the date of the first regular annual meeting of the Company's shareholders in 2023, subject to the reporting person's continued service through such date. Read SEC document |
| April 30, 2021 Filed May 3, 2021 20:14 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantCommon Shares, No Par Value | 7,645 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-014916 · form4.xml · nonDerivative · entry 1 Ross Thomas W. Sr. · CIK 0001669396 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,924 F1 · shares: Represents the award of restricted share units ("RSUs") granted to non-employee directors of the Issuer on the third business day following their election at the Issuer's Annual Meeting of Shareholders. The RSUs have a grant date value equal to $250,000, vest immediately prior to the Issuer's next Annual Meeting of Shareholders, and are settled in common shares, no par value, of the Issuer. Read SEC document |
| May 01, 2020 Filed May 1, 2020 20:32 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantCommon Shares, No Par Value | 11,037 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-015042 · form4.xml · nonDerivative · entry 1 Ross Thomas W. Sr. · CIK 0001669396 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,279 F1 · shares: Represents the award of restricted share units ("RSUs") granted to non-employee directors of the Issuer on the third business day following their election at the Issuer's Annual Meeting of Shareholders. The RSUs have a grant date value equal to $200,000, vest immediately prior to the Issuer's next Annual Meeting of Shareholders, and are settled in common shares, no par value, of the Issuer. Read SEC document |
| March 12, 2020 Filed Mar 16, 2020 20:24 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | PurchaseCommon Stock, No Par Value | 2,500 | $15.54 | $38,837.50 |
DisclosureSEC source: 0001127602-20-010794 · form4.xml · nonDerivative · entry 1 Ross Thomas W. Sr. · CIK 0001669396 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,242 Read SEC document |
| May 03, 2019 Filed May 3, 2019 20:19 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantCommon Stock, No Par Value | 10,633 | $23.51 | $249,981.83 |
DisclosureSEC source: 0001127602-19-017271 · form4.xml · nonDerivative · entry 1 Ross Thomas W. Sr. · CIK 0001669396 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,802 F1 · shares: Represents the award of restricted share units ("RSUs") granted to non-employee directors of Bausch Health Companies Inc. ("Bausch Health") on the third business day following their election at the Annual Meeting of Shareholders of Bausch Health (the "Annual Meeting"). The RSUs have a grant date value equal to $250,000, vest immediately prior to Bausch Health's next Annual Meeting, and are settled in common shares, no par value, of Bausch Health. Read SEC document |
| May 03, 2018 Filed May 4, 2018 22:02 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | GrantCommon Stock, No Par Value | 14,285 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-016413 · form4.xml · nonDerivative · entry 1 Ross Thomas W. Sr. · CIK 0001669396 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,573 F1 · shares: Represents the award of restricted share units ("RSUs") granted to non-employee directors of Valeant Pharmaceuticals International, Inc. ("Valeant") on the third business day following their election at the Annual Meeting of Shareholders of Valeant (the "Annual Meeting"). The RSUs have a grant date value equal to $250,000, vest immediately prior to Valeant's next Annual Meeting, and are settled in common shares, no par value, of Valeant. Read SEC document |
| May 03, 2018 Filed May 8, 2018 20:42 UTC Amendment | Bausch Health Companies Inc. VRX · Entity 4363 | GrantCommon Stock, No Par Value | 13,881 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-016656 · form4a.xml · nonDerivative · entry 1 Ross Thomas W. Sr. · CIK 0001669396 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,169 F1 · shares: Represents the award of restricted share units ("RSUs") granted to non-employee directors of Valeant Pharmaceuticals International, Inc. ("Valeant") on the third business day following their election at the Annual Meeting of Shareholders of Valeant (the "Annual Meeting"). The RSUs have a grant date value equal to $250,000, vest immediately prior to Valeant's next Annual Meeting, and are settled in common shares, no par value, of Valeant. F2 · shares: This Amended Form 4 is being filed to correct the number of RSUs acquired on May 3, 2018 as reported on the Form 4 filed on May 4, 2018. Read SEC document |
| May 05, 2017 Filed May 5, 2017 21:09 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | GrantCommon Stock, no par value | 25,406 | $0.00 | $0.00 |
DisclosureSEC source: 0000885590-17-000026 · primary_doc.xml · nonDerivative · entry 1 Ross Thomas W. Sr. · CIK 0001669396 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,288 F1 · shares: Regular annual Restricted Share Units (RSUs) equal to $250,000 granted to non-employee directors in office on the third trading day following the Annual Meeting of Shareholders based on the closing price of registrant common stock on the date prior to the grant. RSUs represent a contingent right to receive one share of common stock, no par value, of Valeant Pharmaceuticals International, Inc. Read SEC document |
| December 14, 2016 Filed Dec 16, 2016 21:19 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | PurchaseCommon Stock, no par value | 5,000 | $14.73 | $73,650.00 |
DisclosureSEC source: 0001669396-16-000004 · primary_doc.xml · nonDerivative · entry 1 Ross Thomas W. Sr. · CIK 0001669396 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,822 F1 · price: Represents volume-weighted average price of purchases of 5,000 shares of common stock ("Shares") of Valeant Pharmaceuticals International, Inc. (the "Company") at prices ranging from $14.72-$14.74. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of Shares purchased by the reporting person at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.